$18.22 0.2 1.0%
Last Trade - 22/01/21
| Market Cap | ÂŁ571.5m |
| Enterprise Value | ÂŁ540.6m |
| Revenue | ÂŁ4.38m |
| Position in Universe | 2931st / 6630 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 1.68 | 6.15 | 4.23 | 6.29 | 6.16 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. Its drug candidates are ATI-450, ATI-1777, ATI-2138, JAK1/JAK3 Inhibitor, A-101, ATI-501 and ATI-502. Its ATI-450, an investigational oral. small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. Its indirect, wholly owned subsidiary is Confluence Discovery Technologies, Inc.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | July 13, 2012 |
| Public Since | October 7, 2015 |
| No. of Shareholders: | 60 |
| No. of Employees: | 77 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 42,919,291 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 640 Lee Rd Ste 200, WAYNE, 19087-5636, United States |
| Web | https://www.aclaristx.com/ |
| Phone | +1 484 3247933 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 22/01/21, shares in Aclaris Therapeutics Inc are trading at $18.22, giving the company a market capitalisation of ÂŁ571.5m. This share price information is delayed by 15 minutes.
Shares in Aclaris Therapeutics Inc are currently trading at $18.22 and the price has moved by 1.04k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aclaris Therapeutics Inc price has moved by 0.874k% over the past year.
Of the analysts with advisory recommendations for Aclaris Therapeutics Inc, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aclaris Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aclaris Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:
Aclaris Therapeutics Inc does not currently pay a dividend.
Aclaris Therapeutics Inc does not currently pay a dividend.
Aclaris Therapeutics Inc does not currently pay a dividend.
To buy shares in Aclaris Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Aclaris Therapeutics Inc are currently trading at $18.22, giving the company a market capitalisation of ÂŁ571.5m.
Here are the trading details for Aclaris Therapeutics Inc:
Based on an overall assessment of its quality, value and momentum, Aclaris Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Aclaris Therapeutics Inc are currently priced at $18.22. At that level they are trading at 9.77% discount to the analyst consensus target price of 0.00.
Analysts covering Aclaris Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.16 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aclaris Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.612k%. At the current price of $18.22, shares in Aclaris Therapeutics Inc are trading at 0.481k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc's management team is headed by:
Here are the top five shareholders of Aclaris Therapeutics Inc based on the size of their shareholding:
